<code id='DEB28568EA'></code><style id='DEB28568EA'></style>
      • <acronym id='DEB28568EA'></acronym>
      <center id='DEB28568EA'><center id='DEB28568EA'><tfoot id='DEB28568EA'></tfoot></center><abbr id='DEB28568EA'><dir id='DEB28568EA'><tfoot id='DEB28568EA'></tfoot><noframes id='DEB28568EA'>
      • <optgroup id='DEB28568EA'><strike id='DEB28568EA'><sup id='DEB28568EA'></sup></strike><code id='DEB28568EA'></code></optgroup>
        5. <b id='DEB28568EA'><label id='DEB28568EA'><select id='DEB28568EA'><dt id='DEB28568EA'><span id='DEB28568EA'></span></dt></select></label></b><u id='DEB28568EA'></u>
          <i id='DEB28568EA'><strike id='DEB28568EA'><tt id='DEB28568EA'><pre id='DEB28568EA'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          knowledge 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          knowledge  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：671
                                  
                                    
          
                                    
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images
          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.
          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 
          advertisement
          The negotiated prices won’t take effect until 2026. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Laying a path for careers in science
                                
                            
          Next article：  
                                      
                                          Supreme Court strikes down use of affirmative action
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          Wikipedia
          
                  
          

                    
          
            
          
              
                Bright Health sells Medicare Advantage business to Molina
                
          
                        
              
          
                Bright Health sells Medicare Advantage business to Molina
                
          
                  
          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Virtual repurposing can help discover new uses for existing drugs
                
          
                        
              
          
                Virtual repurposing can help discover new uses for existing drugs
                
          
                  
          AdobeTheprocessfordiscoveringdrugstendstobebasedonthesamekindofpigeonholingthatdoctorsusetotreatdise
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                How one medical school became remarkably diverse
                
          
                        
              
          
                How one medical school became remarkably diverse
                
          
                  
          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          CDC panel: People 65 and older should get a Covid spring booster shot
          
            
          AhealthcareworkeradministersaCovid-19boostershot.JensSchlueter/GettyImagesAnexpertpaneladvisingtheCe
          
          
          
          
          
            read more